Therapeutic effect of a novel long-actingGLP-1/GIP/Glucagon triple agonist (HM15211) in CDHFD-induced NASH and fibrosis mice

被引：0

作者：

Choi, J. ^{[1
]}

Jo, H. ^{[1
]}

Kim, J. ^{[1
]}

Kwon, H. ^{[1
]}

Lee, J. ^{[1
]}

Bae, S. ^{[1
]}

Kim, D. ^{[1
]}

Lee, S. ^{[1
]}

Choi, I. ^{[1
]}

机构：

[1] Hanmi Pharm Co Ltd, Hwaseong Si, Gyeonggi Do, South Korea

来源：

DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

127

引用

页码：S64 / S64

页数：1

共 50 条

[41] Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/Glucagon/GIP Tri-Agonist in the MPTP Parkinson's Disease Mouse Model
Lee, Young Mi
Lee, Sang Hyun
Kim, Jeong A.
Choi, In Young
Kim, Young Hoon
Kwon, Se Chang
DIABETES, 2017, 66 : A303 - A303
[42] Neuroprotective effects of HM15211, a novel long-acting GLP-1/Glucagon/GIP tri-agonist in the MPTP Parkinson's disease mouse model
Lee, Y.
Lee, S. -H.
Kim, J.
Choi, I.
Kim, Y.
Kwon, S.
DIABETOLOGIA, 2017, 60 : S579 - S579
[43] Novel Combination of a Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) and Once-Weekly Basal Insulin (HM12460a) Offers Improved Glucose Lowering and Weight Loss in a Diabetic Animal Model
Kim, Jung Kuk
Lee, Jong Suk
Choi, Jaehyuk
Jung, Sung Youb
Lee, Sang Hyun
Choi, In Young
Kim, Sun Jin
DIABETES, 2018, 67
[44] A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (hm15211) in healthy obese subjects
Choi, JaeDuk
Kim, Youngmin
Eun, Kahee
Morrow, Linda
Hompesch, Marcus
Baek, Seungjae
JOURNAL OF HEPATOLOGY, 2020, 73 : S455 - S456
[45] A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects
Choi, Jae Duk
Baek, Seungjae
Kim, Youngmin
Eun, Kahee
Kwon, Se Chang
Morrow, Linda
Hompesch, Marcus
Kang, Jahoon
DIABETES, 2019, 68
[46] Anti-inflammatory and anti-fibrotic effects by simultaneous activation of glucagon, GIP, and GLP-1 of efocipegtrutide (HM15211) in thioacetamide-induced mouse model of liver injury and fibrosis
Kim, Jung Kuk
Kim, Yohan
Lee, Jong Suk
Kwon, Hyunjoo
Park, Eun Jin
Kim, Jeong A.
Bae, Sung Min
Kim, Dae Jin
Lee, Sang Hyun
Choi, In Young
JOURNAL OF HEPATOLOGY, 2023, 78 : S758 - S758
[47] ANTI-INFLAMMATORY AND ANTI-FIBROTIC EFFECTS BY SIMULTANEOUS ACTIVATION OF GLUCAGON, GIP, AND GLP-1 OF EFOCIPEGTRUTIDE (HM15211) IN THIOACETAMIDE-INDUCED MOUSE MODEL OF LIVER INJURY AND FIBROSIS
Kim, Jung Kuk
Kim, Yohan
Kwon, Hyunjoo
Park, Eun Jin
Kim, Jeong A.
Park, Sang Hyun
Bae, Sungmin
Kim, Daejin
Lee, Sang Hyun
Choi, In Young
HEPATOLOGY, 2023, 78 : S1192 - S1193
[48] Therapeutic Potential of HM15275, a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, in Animal Models of Heart Failure
Ye, Byeongjin
Kim, Wonki
Lee, Seon Myeong
Kim, Jeong A.
Kim, Eunseon
Bae, Sungmin
Lee, Sang Hyun
Choi, In Young
DIABETES, 2024, 73
[49] HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
Abdelmalek, Manal
Choi, Jaeduk
Kim, Youngmin
Seo, Kyounghee
Hompesch, Marcus
Baek, Seungjae
JOURNAL OF HEPATOLOGY, 2020, 73 : S124 - S124
[50] Potent Weight Loss Effect and Mechanism of a Novel Long-acting GLP-1/GIP/GCG Triple Agonist, HM15275, in Animal Model of Obesity
Kim, Jung Kuk
Kim, Yohan
Park, Sang Hyun
Park, Eun Jin
Lee, Dahae
Kim, Jeong
Hong, Sung Hee
Bae, Sungmin
Lee, Sang Hyun
Choi, In Young
OBESITY, 2024, 32 : 188 - 188

← 1 2 3 4 5 →